132 related articles for article (PubMed ID: 35038762)
1. Rare Causes of Acute Coronary Syndrome: The JAK2 V617F Mutation-Positive Myeloproliferative Neoplasms: A Cardio-Hematological Perspective.
Cantoni S; Colombo C; Soriano F; Oreglia JA; Sacco A; Veronese S; Brunelli D; Rubboli A; Morici N
Thromb Haemost; 2022 Aug; 122(8):1429-1431. PubMed ID: 35038762
[No Abstract] [Full Text] [Related]
2. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
3. Splenomegaly and the JAK2 V617F mutation.
Langabeer SE
Eur J Intern Med; 2017 Jan; 37():e45-e46. PubMed ID: 27727073
[No Abstract] [Full Text] [Related]
4. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
[TBL] [Abstract][Full Text] [Related]
5. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
6. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
[TBL] [Abstract][Full Text] [Related]
7. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?
Langabeer SE
Eur J Intern Med; 2018 Jun; 52():e37-e38. PubMed ID: 29622375
[No Abstract] [Full Text] [Related]
8. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
Foucar CE; Stein BL
JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
[No Abstract] [Full Text] [Related]
9. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
10. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
11. [Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases].
Olkhovskiy IA; Gorbenko AS; Stolyar MA; Grischenko DA; Tkachenko OA; Martsinkevich TL
Ter Arkh; 2019 Jul; 91(7):25-28. PubMed ID: 32598732
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
[TBL] [Abstract][Full Text] [Related]
13. Plummer-Vinson syndrome and reactive thrombocytosis mask a JAK2-V617F positive myeloproliferative neoplasm.
Scott EC; Schuster S
Blood; 2011 Dec; 118(23):5988. PubMed ID: 22238785
[No Abstract] [Full Text] [Related]
14. Neutrophilia and the JAK2 V617F Mutation.
Langabeer SE; Haslam K
Pathol Oncol Res; 2019 Jan; 25(1):437-438. PubMed ID: 28944411
[No Abstract] [Full Text] [Related]
15. [JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
Spasovski V; Tosić N; Kostić T; Pavlović S; Colović M
Srp Arh Celok Lek; 2010; 138(9-10):614-8. PubMed ID: 21180092
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
[TBL] [Abstract][Full Text] [Related]
17. JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.
Ar MC; Hatemi G; Ekizoğlu S; Bilgen H; Saçli S; Buyru AN; Soysal T; Ülkü B; Yazici H
Clin Appl Thromb Hemost; 2012 Jul; 18(4):421-6. PubMed ID: 22203033
[TBL] [Abstract][Full Text] [Related]
18. Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Reading NS; Lim MS; Elenitoba-Johnson KS
Mol Diagn Ther; 2006; 10(5):311-7. PubMed ID: 17022694
[TBL] [Abstract][Full Text] [Related]
19. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]